Sees FY25 revenue $3B-$3.1B, consensus $2.92B. Sees FY25 adjusted EBITDA $650M-$675M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- AMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
- Robust Growth and Strategic Positioning Drive Buy Rating for Amneal Pharmaceuticals
- Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
- Amneal gets FDA approval for memantine/donepezil extended-release capsules